Racial/ethnic differences in fibrosis prevalence and progression in biopsy‐proven steatosis: A focus on the Asian American population

Rebecca G. Kim, Janet N. Chu, Eric Vittinghoff, Jasmine Deng, Jewel N. Reaso, James P. Grenert, Mandana Khalili – 9 September 2022 – Fatty liver disease (FLD) is a leading cause of chronic liver disease (CLD) globally, and vulnerable populations are disproportionately affected. Prior studies have suggested racial/ethnic differences in FLD prevalence and severity; however, these studies often excluded Asian Americans.

High reproducibility of spleen stiffness measurement by vibration‐controlled transient elastography with a spleen‐dedicated module

Cristina Rigamonti, Micol Giulia Cittone, Giulia Francesca Manfredi, Andrea Sorge, Riccardo Moia, Andrea Patriarca, Maria Francesca Donato, Gianluca Gaidano, Mario Pirisi, Mirella Fraquelli – 8 September 2022 – Spleen stiffness measurement (SSM) by vibration‐controlled transient elastography (VCTE) is a noninvasive technique for estimating portal hypertension in patients with chronic liver disease (CLD), with its reproducibility yet to be established and its feasibility still unknown beyond CLD.

Risk stratification and early detection biomarkers for precision HCC screening

Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, Yujin Hoshida – 8 September 2022 – Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi‐annual HCC screening in at‐risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival.

High frequency of acute decompensation and cancer in patients with compensated cirrhosis due to nonalcoholic fatty liver disease: A retrospective cohort study

Octavi Bassegoda, Jesús Rivera‐Esteban, Isabel Serra, Rosa Morillas, Teresa Broquetas, Mercedes Vergara, Adrià Rodriguez, Carles Aracil, Silvia Virolés, Jose A. Carrión, Albert Pardo, Sergio Rodríguez‐Tajes, Miquel Serra‐Burriel, Juan M. Pericàs, Salvador Augustin, Pere Ginès, Isabel Graupera – 7 September 2022 – The natural history of compensated cirrhosis due to nonalcoholic fatty liver disease (NAFLD) has not been completely characterized.

Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease

Daniel H. Leung, Sridevi Devaraj, Nathan P. Goodrich, Xinpu Chen, Deepthi Rajapakshe, Wen Ye, Victor Andreev, Charles G. Minard, Danielle Guffey, Jean P. Molleston, Lee M. Bass, Saul J. Karpen, Binita M. Kamath, Kasper S. Wang, Shikha S. Sundaram, Philip Rosenthal, Patrick McKiernan, Kathleen M. Loomes, M. Kyle Jensen, Simon P. Horslen, Jorge A. Bezerra, John C. Magee, Robert M. Merion, Ronald J. Sokol, Benjamin L. Shneider, The Childhood Liver Disease Research Network – 6 September 2022

The discriminatory ability of FibroScan liver stiffness measurement, controlled attenuation parameter, and FibroScan–aspartate aminotransferase to predict severity of liver disease in children

Alexander Chaidez, Zhaoxing Pan, Shikha S. Sundaram, Julia Boster, Mark Lovell, Ronald J. Sokol, Cara L. Mack – 6 September 2022 – Vibration controlled transient elastography (FibroScan) is used to predict the severity of liver fibrosis and steatosis. In pediatrics, few studies have been performed directly comparing liver histologic features with FibroScan liver stiffness measurements (LSMs) and controlled attenuation parameters (CAPs).

Subscribe to